FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912346848> ?p ?o ?g. }

• W2912346848 endingPage "64" @default.
• W2912346848 startingPage "53" @default.
• W2912346848 abstract "Summary Rituximab monotherapy has proven efficacy in treatment‐naïve, asymptomatic advanced‐stage follicular lymphoma ( FL ). Ofatumumab is a fully humanized anti‐ CD 20 monoclonal antibody with increased CD 20 affinity and complement‐dependent cytotoxicity. This phase 2 trial ( NCT 01190449) evaluated ofatumumab in patients with untreated, low/intermediate‐risk FL International Prognostic Index ( FLIPI ), advanced‐stage FL to determine single‐agent efficacy. Patients with measurable disease in stages III / IV or bulky stage II , regardless of Groupe d'Etude des Lymphomes Folliculaires criteria, received 4 weekly 1000 mg doses followed by four extended induction doses once every 8 weeks. Primary endpoint was overall response rate ( ORR ) to 1000 mg; secondary endpoints were progression‐free survival ( PFS ) and safety. Fifty‐one patients were enrolled. Fifteen patients were randomized to 500 mg prior to discontinuing that arm for slow accrual. Among 36 patients on the 1000 mg arm, ORR was 84%, median PFS was 1·9 years and median response duration was 23·7 months. All patients remain alive. No grade 4 infusion reactions or grade 3/4 infections occurred. Grade 3 infusion reactions occurred in 25% in the 1000 mg arm only (all first infusion); all but two patients continued on study. Discontinuation was 6% for the total study population. Ofatumumab monotherapy administered by extended induction in untreated, low/intermediate‐risk FLIPI , advanced‐stage FL is well tolerated and active. Activity appears similar to that reported with single‐agent rituximab." @default.
• W2912346848 created "2019-02-21" @default.
• W2912346848 creator A5005159945 @default.
• W2912346848 creator A5005446802 @default.
• W2912346848 creator A5015361329 @default.
• W2912346848 creator A5019935261 @default.
• W2912346848 creator A5023313666 @default.
• W2912346848 creator A5027080346 @default.
• W2912346848 creator A5037882455 @default.
• W2912346848 creator A5043991433 @default.
• W2912346848 creator A5056567340 @default.
• W2912346848 creator A5082606841 @default.
• W2912346848 date "2019-02-05" @default.
• W2912346848 modified "2023-10-16" @default.
• W2912346848 title "Phase 2 multicentre study of single‐agent ofatumumab in previously untreated follicular lymphoma:<scp>CALGB</scp>50901 (Alliance)" @default.
• W2912346848 cites W1593874097 @default.
• W2912346848 cites W1875927722 @default.
• W2912346848 cites W1885678484 @default.
• W2912346848 cites W1915689252 @default.
• W2912346848 cites W1965235365 @default.
• W2912346848 cites W2030638302 @default.
• W2912346848 cites W2073019775 @default.
• W2912346848 cites W2104334201 @default.
• W2912346848 cites W2107698216 @default.
• W2912346848 cites W2114233385 @default.
• W2912346848 cites W2126529136 @default.
• W2912346848 cites W2126960075 @default.
• W2912346848 cites W2133201432 @default.
• W2912346848 cites W2136326451 @default.
• W2912346848 cites W2138404218 @default.
• W2912346848 cites W2165916281 @default.
• W2912346848 cites W2167635913 @default.
• W2912346848 cites W2198559016 @default.
• W2912346848 cites W2264636885 @default.
• W2912346848 cites W2510720247 @default.
• W2912346848 cites W2597391618 @default.
• W2912346848 cites W2761878534 @default.
• W2912346848 cites W4237219860 @default.
• W2912346848 cites W4293203547 @default.
• W2912346848 cites W4293241248 @default.
• W2912346848 doi "https://doi.org/10.1111/bjh.15768" @default.
• W2912346848 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6462222" @default.
• W2912346848 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30723894" @default.
• W2912346848 hasPublicationYear "2019" @default.
• W2912346848 type Work @default.
• W2912346848 sameAs 2912346848 @default.
• W2912346848 citedByCount "7" @default.
• W2912346848 countsByYear W29123468482020 @default.
• W2912346848 countsByYear W29123468482021 @default.
• W2912346848 countsByYear W29123468482022 @default.
• W2912346848 crossrefType "journal-article" @default.
• W2912346848 hasAuthorship W2912346848A5005159945 @default.
• W2912346848 hasAuthorship W2912346848A5005446802 @default.
• W2912346848 hasAuthorship W2912346848A5015361329 @default.
• W2912346848 hasAuthorship W2912346848A5019935261 @default.
• W2912346848 hasAuthorship W2912346848A5023313666 @default.
• W2912346848 hasAuthorship W2912346848A5027080346 @default.
• W2912346848 hasAuthorship W2912346848A5037882455 @default.
• W2912346848 hasAuthorship W2912346848A5043991433 @default.
• W2912346848 hasAuthorship W2912346848A5056567340 @default.
• W2912346848 hasAuthorship W2912346848A5082606841 @default.
• W2912346848 hasBestOaLocation W29123468481 @default.
• W2912346848 hasConcept C126322002 @default.
• W2912346848 hasConcept C141071460 @default.
• W2912346848 hasConcept C168563851 @default.
• W2912346848 hasConcept C203092338 @default.
• W2912346848 hasConcept C2776694085 @default.
• W2912346848 hasConcept C2777058707 @default.
• W2912346848 hasConcept C2777063308 @default.
• W2912346848 hasConcept C2778714382 @default.
• W2912346848 hasConcept C2778715236 @default.
• W2912346848 hasConcept C2779338263 @default.
• W2912346848 hasConcept C2780653079 @default.
• W2912346848 hasConcept C2908647359 @default.
• W2912346848 hasConcept C31760486 @default.
• W2912346848 hasConcept C535046627 @default.
• W2912346848 hasConcept C71924100 @default.
• W2912346848 hasConcept C90924648 @default.
• W2912346848 hasConcept C99454951 @default.
• W2912346848 hasConceptScore W2912346848C126322002 @default.
• W2912346848 hasConceptScore W2912346848C141071460 @default.
• W2912346848 hasConceptScore W2912346848C168563851 @default.
• W2912346848 hasConceptScore W2912346848C203092338 @default.
• W2912346848 hasConceptScore W2912346848C2776694085 @default.
• W2912346848 hasConceptScore W2912346848C2777058707 @default.
• W2912346848 hasConceptScore W2912346848C2777063308 @default.
• W2912346848 hasConceptScore W2912346848C2778714382 @default.
• W2912346848 hasConceptScore W2912346848C2778715236 @default.
• W2912346848 hasConceptScore W2912346848C2779338263 @default.
• W2912346848 hasConceptScore W2912346848C2780653079 @default.
• W2912346848 hasConceptScore W2912346848C2908647359 @default.
• W2912346848 hasConceptScore W2912346848C31760486 @default.
• W2912346848 hasConceptScore W2912346848C535046627 @default.
• W2912346848 hasConceptScore W2912346848C71924100 @default.
• W2912346848 hasConceptScore W2912346848C90924648 @default.
• W2912346848 hasConceptScore W2912346848C99454951 @default.
• W2912346848 hasFunder F4320337351 @default.
• W2912346848 hasIssue "1" @default.

• next